A Cross-sectional Analysis of Treatment in PUPs in 2021 in Germany - First Data from the GEPHARD Study Group

Königs, Christoph; Bidlingmaier, Christoph; Aumann, Volker; Behnisch, Wolfgang; Bührlen, Martina; Chada, Martin; Halimeh, Susan; Heine, Sabine; Heller, Christine; Holzhauer, Susanne; Holzschuh, Linus; Horneff, Silvia; Hütker, Sebastian; Kentouche, Karim; Kim, Sorah; Klamoth, Robert; Knöfler, Ralf; Kramer, Sonja; Kurnik, Karin; Oldenburg, Johannes; Olivieri, Martin; Schultze-Strasser, Stephan; Türknetz, Mira; Vaillant, Vera; Wiegering, Verena; Wieland, Ivonne; Zierk, Jakob; Eberl, Wolfgang; Laws, Hans-Jürgen; Sigl-Krätzig, Michael; Wermes, Hannover Cornelia; Zieger, Barbara; Demir, Eren; Hassenpflug, Wolf; Schober, Sarah; Escuriola-Ettingshausen, Carmen und Sparber-Sauer, Monika (2022): A Cross-sectional Analysis of Treatment in PUPs in 2021 in Germany - First Data from the GEPHARD Study Group. In: Hämostaseologie, Bd. 42, Nr. SUPPL 1: S24-S31

Abstract

Objectives Initial treatment in patients with haemophilia remains challenging. The choice of therapy, timing, dose and frequency have been and are still under intense debate. New treatment options like novel factor concentrates and non-factor therapies broaden the discussion. Design The German Paediatric Haemophilia Research Database (GEPHARD) is a multicentre prospective observational study including children and adolescents with haemophilia A or B (FVIII or FIX levels < 25 IU/dL) in a German treatment centre after January 1st, 2017. A cross-sectional analysis was performed in June 2021. Results 249 children and adolescents from 22 participating centres in Germany were analysed in this cross-sectional analysis. 203 patients suffered from haemophilia A (PwHA) and 46 from haemophilia B (PwHB). The median age at diagnosis for Pw severe HA or HB was 6 or 2 months, the median age at analysis was 33 or 35 months for Pw severe HA or B, respectively. 117 Pw severe HA received treatment, including plasma derived concentrates (n = 43), standard recombinant concentrates (n = 23), extended half live concentrates (n = 33) and non-replacement therapies (n = 18). For Pw severe HB, plasma derived concentrates (n = 3), standard recombinant concentrates (n = 8) and extended half live concentrates (n = 14) were used. Current inhibitors were reported in 16 PwHA and 1 PwHB. Conclusions GEPHARD was successfully established as a national cohort for newly diagnosed PwH in Germany. Epidemiological and treatment data were presented. Longitudinal analyses of this growing cohort will allow to value treatment strategies and their outcome in the evolving treatment landscape.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0720-9355
• Sprache: Englisch